How Trump Accidentally Declared War on Mar-a-Lago Face

On the night of February 28, Mar-a-Lago hosted two parties at once. On one side of the Palm Beach estate, guests in gowns and black tie sipped cocktails by the pool at a charity gala. On the other, the President of the United States started a war.

The White House released the photographs of the latter event-Donald Trump flanked by his Secretary of State and chief of staff, monitoring “Operation Epic Fury” as American B-2s and Israeli forces struck Iran and killed its supreme leader. National-security veterans may have got, in CNN’s word, “agita” at the idea of club members steps from the country’s most sensitive secrets.

Today marks the 100th day of the war with Iran.

But that was not only the war Trump had launched that might have interested guests at Mar-a-Lago. Months earlier, from the Resolute Desk in Washington, he had launched another: a trade war, fought with tariffs, against some of the countries that manufacture the things his inner circle injects into its faces.

“Mar-a-Lago face” is the pillow-lipped, glass-cheeked, forehead-frozen look which is, say critics, personified by Kristi Noem, Kimberly Guilfoyle, Matt Gaetz and the rest of the president’s polished court.

This is the stranger side of Trump’s wars, both hot and economic. They’re an aesthetic of chaos and the crossfire lands everywhere. But it doesn’t land equally.

Common Knowledge

The common argument about this is about affordability and Trump is fighting it on two fronts that he opened himself.

The Iran war pushed gas past $4 a gallon, the highest since 2022, with prices now expected to stay elevated all year. Inflation reached a three-year high of 3.8 percent by late April. The tariffs behave like a tax and the nonpartisan Tax Foundation estimates they cost the average household, not the Mar-a-Lago elite, roughly $1,000 in 2025 and another $1,300 in 2026.

Representative Tom Suozzi, a New York Democrat who had cautiously backed the Iran strikes, told The New York Times the pain was “a very real-life consequence of some of the actions being taken by the administration.” The Democrats’ House campaign committee is running pump-price ads across four dozen battleground districts.

The administration wants everyone to calm down. Touring the $400 million ballroom he is adding to the White House, the president waved off the spike: “This is peanuts.” Quieter voices say the war shouldn’t move U.S. prices at all, since America is a net oil exporter.

Both sides have a point: crude has fallen roughly 20 percent from its 2026 peak, and the dreaded tariff-inflation tsunami never quite made landfall, with even former Fed Chair Jerome Powell, no ally of Trump, saying the effect might be small and temporary.

But the left isn’t wrong that it’s real money: the EIA still projects $3.88 gas against a pre-war $2.91, and the war alone adds about 0.6 points to inflation, tariffs on top.

Uncommon Knowledge

Those are the numbers everyone knows about. The Mar-a-Lago look lifts a veil on how complicated the situation has become.

The aesthetic depends on three pillars (Botox, fillers and surgery), all of which have connections overseas.

The fundamental ingredient is Botox. A heavy upper-face treatment runs around 64 units, fades in three to four months, and at the $16–$25 per unit premium injectors charge quickly adds up, generally to more than $3,000 a year for three sessions.

Nearly every vial of brand-name Botox is made in a single Allergan plant in Westport, Ireland, the only site on the planet that produces it. When Trump imposed his pharmaceutical tariff, which amounted to 100 percent on patented drugs, capped at 15 percent for the EU, Ireland’s vital pharma sector braced.

He had wanted this for years, marveling that tiny Ireland held the American drug industry “in its grasp.”

But Botox got a pass. In January, AbbVie, Allergan’s giant American owner, struck a three-year agreement with the administration: $100 billion in U.S. investment and a seat on the TrumpRx platform in exchange for “exemption from tariffs and future pricing mandates.”

The agreement is confidential but, on its face, the single most important, most imported component of the Mar-a-Lago look is one the tariff no longer reaches.

Challengers weren’t as fortunate. AbbVie’s Juvéderm filler has the same exemption but Galderma’s Restylane and Sculptra do not: the company’s own 2026 guidance assumes a 15 percent U.S. tariff on their import value, while calling the exposure “manageable.” Revance’s RHA filler is made in Switzerland and therefore exposed, while its DAXXIFY neuromodulator is U.S.-made and escapes the levy.

Mar-a-Lago Face a Brand Lottery

In this confusing tangle of policy and reverse-policy and country of origin, the tariff on the Mar-a-Lago Face is, in effect, a brand lottery. Pick the incumbent’s products and pay nothing; pick a European challenger and pay 15 percent on the wholesale, perhaps $40 to $55 a syringe.

How much the Mar-a-Lago set will feel this is not clear. It’s the problem with tariffs made visible.

“Tariffs have absolutely put pressure on the aesthetics supply chain-but not in the way most headlines suggest,” Lindsay Nahmiache, CEO of Veriphy, a Canadian biotech skincare company that exports to the U.S., told Newsweek.

“This isn’t a category where costs get cleanly passed through to consumers. It’s a margin-managed business, and the major players are highly incentivized to protect price stability, especially on flagship treatments such as Botox.

Market Insulation

“AbbVie securing exemptions is a meaningful strategic advantage. It insulates them from the kind of input volatility that smaller or newer competitors still have to navigate, particularly around imported raw materials. In a market where consistency, brand trust, and predictable pricing drive demand, that kind of insulation matters-it reinforces Botox’s position as the category anchor.

“In reality, tariffs haven’t reshaped pricing as much as they’ve reinforced who has the leverage to control it.”

She added that “over time, that dynamic concentrates pricing power and distribution control in the hands of a few dominant players, reinforcing a winner-takes-most structure across both aesthetics and pharma.”

Safe embed will be rendered here

Service URL: https://public.flourish.studio/visualisation/29247994/embed

Hormuz Disruption Pushes Up Medical Costs

That leaves facelifts, where, like Middle East tensions, costs can escalate rapidly. They generally range at $25,000 to $40,000 at the premium tier, with surgeon’s fees accounting for a high proportion.

This also is where the hot war finally shows up, though sadly for Trump’s opponents, only faintly. Cosmetic medicine runs on petroleum: the syringes, cannulas, IV bags and sterile packaging are oil-derived plastics, and the Strait of Hormuz disruption pushed medical-grade plastic costs up roughly 13 to 27 percent per pound, with energy and diesel freight rising alongside.

The bulk of 2026’s price growth, the industry says, is post-pandemic inflation and demand, not Hormuz, but Hormuz has made it worse. Not that the elite will be too worried.

“A $250 annual increase for a filler patient or a $500 increase in a facelift is not likely to meaningfully change decision-making in a highly specialized surgical practice like mine,” Dr. Rian A. Maercks, board-certified plastic surgeon and founder of The Maercks Institute in Miami, told Newsweek.

“Where this becomes much more disruptive is the lower-margin med-spa and discount injectable market. In that environment, a relatively small increase in product cost can meaningfully compress profit margins. A $250 yearly increase may not change the behavior of a high-end surgical patient, but it can absolutely affect the consumer who is shopping Botox or filler by price.”

He added that “tariffs are one piece of a much larger cost picture [and] I would not blame tariffs alone. They are an accelerant layered on top of an already inflated operating environment.”

The Impact of Rising Costs on Patients

So will clients be dissuaded by an increase of a few hundred dollars on their annual cost? “At the premium end, probably not very much,” Maercks said.

“But in the mass-market injectable space, yes, it could matter. Patients may stretch intervals, reduce units, choose fewer syringes, switch products, or become more conservative. Some may move away from routine maintenance entirely.

“Discount med spas often rely on volume, thin margins, and frequent repeat visits. If product costs rise and consumers resist higher pricing, those practices can get squeezed very quickly.

“Patients are not buying units or syringes. They are buying judgment, safety, artistry, and a result. That distinction matters.” That’s the problem with tariffs. They hit the little people most.

The left’s argument that “these wars are bankrupting families” is true at the pump and elsewhere. Pushed by the war’s energy shock and the slow pass-through of tariffs, U.S. consumer prices rose 3.8 percent in the year to April. Gasoline ran 28 percent higher than a year earlier and electricity 6 percent.

At the grocery store the war arrived clearly: beef climbed nearly 15 percent, coffee 18.5 percent, and refrigerated produce took the worst of it, with blueberries up 29 percent, tomatoes close to 40 percent.

These are real rises. They strain families. But they are not a return to the pandemic-driven inflation of the Biden era.

Yet the right’s argument that “it’s temporary” misses the most corrosive effect of the tariffs mess: they can turn into competitive advantages for the dominant sellers.

So Trump did, in a sense, declare war on Mar-a-Lago Face, once from a war room and once from a desk, without meaning either. But on the evidence, the only combatant who clearly came out ahead amid the crossfire was a market-leading pharmaceutical company. Everyone else is paying for the wars, whether they can afford to or not.

2026 NEWSWEEK DIGITAL LLC.

This story was originally published June 7, 2026 at 5:00 AM.